Phase A — Understand the business
Lens 1 · Company Overview
Quantum Computing Inc ("QCi") is a Hoboken, NJ photonics company that builds room-temperature quantum-optimization and photonic-sensing hardware, and is standing up a thin-film-lithium-niobate (TFLN) chip foundry. It is not a gate-model quantum-computing company.
The product line, all derived from its "Core Photonics Technology" (conditioning/manipulating/measuring single and entangled photons):
- Entropy Quantum Computer ("Dirac" platform) — a photonic optimization machine using controlled feedback through energy loss in a photonic loop. Dirac-3 launched Q1-2024; Dirac-4 in development. Sold cloud-based and as a rack-mountable on-prem box requiring no cryogenics. The pitch is size/weight/power/cost advantage over superconducting (IBM/Google), ion-trap (IonQ/Quantinuum) and annealing (D-Wave) architectures.
- Reservoir-computing AI edge device — "Emucore" (2023), refreshed as "Neurawave" in Nov 2025, a photonic recurrent-neural-net accelerator.
- Photonic sensing — a LiDAR system and a Quantum Photonic Vibrometer (remote vibration sensing via single-photon counting), plus a quantum-networking / quantum-authentication prototype.
- TFLN Foundry Services — the "AZ Chips Facility," a leased TFLN prototyping/small-batch fab in Arizona State University's Research Park (Tempe), buildout "substantially completed" March 2025; a higher-volume "FAB 2" is in planning.
Contract structure: Revenue is project-based — multi-month proof-of-concept and R&D-services contracts plus hardware sales (vibrometers, quantum-networking devices) to "multiple commercial and government customers." No recurring/take-or-pay base; revenue is described as "slow to develop" because customers proceed with "small, exploratory contracts". The company began recognising cloud Dirac-3 access revenue in 2025.
The number that frames everything: FY2025 total revenue was $682 thousand (Services $368K + Products $314K). This is a pre-commercial company by any operating definition.
Feb 2026 — LSI acquisition (material change): QCi acquired Luminar Semiconductor, Inc. ("LSI") for $110 million in cash ($11M escrow), closed Feb 2, 2026, via a Section 363 Bankruptcy-Court-supervised sale out of Luminar Technologies (the LiDAR SPAC). LSI brings an in-house III-V photonic-semiconductor fab in Santa Barbara, advanced packaging, and an existing aerospace-and-defense / optical-comms customer base. This is the first real revenue engine QCi has owned — and it was bought distressed.
Lens 2 · Supply Chain
Named stakeholders along the chain:
Upstream inputs →
- TFLN wafers / lithium niobate substrate — crystalline thin-film lithium niobate is the core material for the AZ foundry; QCi notes single-/limited-source supplier risk for key components but does not name the wafer supplier in the 10-K.
- III-V compound semiconductor inputs — post-LSI, QCi has its own III-V fab (laser diodes, semiconductor optical amplifiers, avalanche photodiodes), pulling it partway upstream and reducing dependence on external photonic-component vendors.
- Lab/fab capital equipment — depreciation on long-lived lab equipment is a rising R&D cost line, implying meaningful tool vendors (unnamed).
→ QCi (Hoboken HQ; Tempe AZ foundry; Santa Barbara LSI fab) →
→ End customers:
- Government / defense — NASA is the most-cited counterparty (and the most contested — see Lens 10/13); LSI explicitly serves "aerospace and defense."
- Commercial / research — universities, research institutions, early-adopter enterprises running PoCs.
customers.csv is empty (no disclosed concentration), but qualitative disclosure says revenue comes from a small number of exploratory contracts — i.e. high implicit concentration.
Chokepoints / single-source dependencies: (1) the TFLN material and the foundry-tooling supply chain (the foundry is the differentiator and the most-attacked claim); (2) its own balance sheet — the real "supplier" funding this company is the equity market. With $682K of revenue against $51M operating spend, QCi's "supply chain" upstream is dilution, not materials (see Lens 5).
Lens 3 · Competitive Advantages (moats)
The claimed moat: room-temperature, low-power photonic architecture (size/weight/power/cost advantage), plus a vertically-integrated TFLN photonics platform — discrete-component EQC migrating onto in-house TFLN PICs, now fed by LSI's III-V fab and packaging. The IP estate: patents + trade secrets; three registered trademarks (QPhoton, QGraph, Qatalyst); the EQC method is "patent-pending".
Honest moat assessment — thin and unproven:
- No scale moat. $682K revenue vs. competitors with longer operating histories and "significantly greater financial, technical, product-development and marketing resources" — the 10-K says this explicitly. The Quantum Insider counts ~700 companies / ~400 pure-play quantum firms — this is a crowded field, not a protected niche.
- No switching-cost / network moat. Exploratory PoC contracts with no recurring base = customers can walk.
- Possible process/IP moat in TFLN — if the AZ foundry is genuinely differentiated and scales. This is precisely the claim two short-sellers say is fabricated (Lens 10/13). Unverifiable from outside; the burden of proof sits with QCi.
- Bargaining power: weak both ways. It needs customers far more than they need it (a $26K-scale government contract is a "win"); upstream, owning the LSI III-V fab is the one genuine structural improvement — it gives QCi a captive component source and a real, if distressed, manufacturing capability.
The actual edge is financial, not technological: ~$1.5B of liquidity (Lens 5). That is a moat against bankruptcy and a moat of time — it buys years of runway to try to make the technology real. It is not a moat against competition.
Lens 4 · Segments
The company reports as a single operating and reportable segment at the consolidated level. segments.csv is empty — consistent with single-segment reporting. The only available split is the revenue-type breakout:
| Revenue type | FY2025 | FY2024 | YoY |
|---|
| Services | $368K | $346K | +6% |
| Products | $314K | $27K | +1,063% |
| Total | $682K | $373K | +83% |
Trend & cause: Products revenue exploded off a $27K base because QCi shipped vibrometer and quantum-networking devices in 2025 and began selling "off-the-shelf" units rather than bespoke services. Services growth (+6%) was flat. The +83% headline is real but immaterial in absolute terms — a rounding error against a $51M cost base.
Post-LSI the segment picture changes materially: Q1-2026 total revenue was $3,691K vs. $39K in Q1-2025 — a ~95× jump driven almost entirely by newly-consolidated LSI photonics-component revenue, not organic quantum/foundry sales. Going forward, LSI's aerospace/defense/optical-comms book will be the bulk of "revenue," and the quantum story will be a separate, still-pre-commercial line. Watch whether QCi starts segment-reporting LSI separately — single-segment reporting that buries a distressed acquisition's revenue inside a "quantum" headline is itself a flag (Lens 10).
Phase B — Measure performance
Lens 5 · Earnings Result (FY2025 10-K + Q1-2026 10-Q)
FY2025 income statement:
- Total revenue $682 | Gross profit $67 (10% margin, down from 30% — first-unit assembly costs) | Cost of revenue $615
- R&D $20,473 (+81%) | S&M $3,431 (+89%) | G&A $27,240 (+111%, driven by controls/accounting build-out, financing/M&A legal, and litigation)
- Total operating expenses $51,144 → Loss from operations $(51,077)
- Non-operating: Interest & other income +$20,718 (on the cash hoard) | Change in FV of derivative/warrant liability +$11,750 (non-cash mark on QPhoton warrants) | Interest expense $(65)
- Net loss $(18,674) — i.e. the headline net loss is less than half the operating loss, flattered by
$32.4M of non-operating items ($20.7M interest income + ~$11.75M non-cash warrant gain).
The single most important read: the $(18.7M) net loss is not the run-rate. Strip the non-operating noise and the business burned ~$51M operating in FY2025. The warrant gain reverses to a loss if the stock rises above the $10.26 Dec-31 bid — so a rising share price mechanically worsens reported net loss.
Balance sheet (12/31/2025):
- Cash & equivalents $737.9M + short/long-term investments $782.5M = ~$1.52B liquidity
- Total current assets $1,133.7M vs. current liabilities $11.1M → working capital $1,122.6M
- Total stockholders' equity $1,598.3M; accumulated deficit $(219.2M)
- Derivative liability $7.8M; effectively no debt (no lines of credit, no short-term debt)
- How it got there: raised net $1,475.1M in 2025 by selling 86.3M shares of common stock.
Q1-2026 update (latest print, 10-Q filed 2026-05-11):
- Revenue $3,691K (vs $39K Q1-25) — LSI-driven
- Loss from operations $(20,550K) (vs $(8,286K)) — opex more than doubled YoY with LSI integration + scaling
- Cash $257.7M (down from $737.9M — the $110M LSI cash purchase + burn + reallocation into investments; investments still ~$1.2B)
- Shares outstanding 225,534,987 as of the 10-Q cover (8 May 2026)
Flags vs. its own history: (1) operating cash burn accelerating ($30.3M used in ops FY25 vs $16.2M FY24, and Q1-26 operating loss alone $20.6M); (2) gross margin collapsed to 10%; (3) the entire "earnings improvement" (net loss −73% YoY) is an artifact of interest income + a warrant swing, not operations.
Market reaction context: consensus/transcripts unavailable on disk (transcripts/ empty); QUBT has no meaningful sell-side EPS consensus — it trades on theme and headline flow, not numbers.
Lens 6 · Earnings Calls (sentiment trend)
transcripts/ is empty — no call transcripts on disk, and QCi's calls are not a primary price driver (the stock moves on sector flow and short reports, not guidance). From the filings' own narrative, management's consistent focus is: "quantum-ready solutions for solving real-world problems," the TFLN foundry build-out, the product roadmap (Dirac-4, Neurawave), and — increasingly in FY2025 — building out financial controls and accounting staff (a tell that the prior controls were inadequate; see Lens 10).
What they started saying more of: capital deployment (FAB 2, "high-volume chip manufacturing facility"), M&A ("acquire complimentary businesses"), and — post-Iceberg/Capybara — defensive framing around the foundry being real and customer revenue being "slow to develop." What is conspicuously absent: any disclosed marquee, named, multi-year commercial customer or backlog figure. `` sentiment: analysts (Rosenblatt's John McPeake, Buy, PT $22) frame the story around "upcoming product launches and commercial adoption" — i.e. all forward, nothing in the trailing numbers. Honest read: management tone is promotional-forward; the gap between narrative and the $682K P&L is the entire short thesis.
Lens 7 · Comps
Pure-play quantum cohort. Multiples are `` with date or n/a. All four are pre-profit and trade on theme; P/S figures are extreme and not value-investing inputs — they are sentiment gauges.
| Company | Ticker | Mkt cap | Latest rev | P/S | EV/EBIT | P/E | Div |
|---|
| Quantum Computing Inc | QUBT | ~$2.5B | $0.682M FY25 / $3.69M Q1-26 (LSI) | ~3,670× on FY25 rev; ~170× on annualized Q1-26 LSI rev | neg (op loss) | neg | 0 |
| IonQ | IONQ | ~$21.5B | ~$130M 2025; Q1-26 $64.7M | ~109–126× | neg | neg | 0 |
| Rigetti | RGTI | ~$7.67B | $4.4M Q | ~836× | neg | neg | 0 |
| D-Wave Quantum | QBTS | ~$5.27B | ~$22.3M LTM; $2.86M Q1-26 (−81% YoY) | ~791× | neg | neg | 0 |
5-yr avg ROE: n/a (all four have negative equity returns / short public histories; meaningless for pre-revenue names).
What the table says: QUBT is the smallest of the cohort by market cap and by orders of magnitude the most expensive on revenue — its ~$2.5B cap sits on the least organic revenue of the four. Even on the LSI-inflated Q1-26 run-rate it is richer than IonQ on a per-dollar-of-revenue basis. The comp set's saving grace for QUBT bulls: this entire cohort is priced on TAM and theme, so "expensive vs. revenue" is the cohort's baseline, not an outlier — but QUBT is the extreme of an already-extreme group.
Lens 8 · Stock-Price Catalysts (what actually moves QUBT)
QUBT is a high-beta theme stock; it "routinely moves 10-15% on no news". The >5% movers over the cycle:
- Late-2024 → 2025 quantum melt-up — sector-wide; QUBT ran toward its $25.84 52-wk high.
- Nov 2024 — Iceberg Research short report ("perma-scam," foundry "will amount to nothing") — sharp drop.
- Jan 16–17, 2025 — Capybara Research short report ("rampant fraud") — −5.8% then ~−10%.
- Feb 25, 2025 — securities class action filed — overhang.
- 2025 — US-government quantum-stake / National-Quantum-Initiative-driven sector rally — broad lift across IONQ/RGTI/QBTS/QUBT.
- May 21, 2026 — "quantum trade roars back" — QUBT +14% in a single session, D-Wave +25%, Rigetti +24%.
- June 16, 2026 — rally reversal — whole cohort −5% to −7%; earlier, Quantinuum (QNT) breaking its IPO price triggered a sector selloff.
Pattern / what the market reacts to: (1) sector sentiment and government/policy headlines (the dominant driver — QUBT trades as a basket constituent, not on its own fundamentals); (2) short-seller reports (asymmetric downside catalyst, still live via the litigation); (3) capital-markets events (raises, the QNT IPO break). Company-specific operating news barely registers because there is barely any operating performance to react to. Implication for a position: this is a sentiment/flow instrument with a fraud-allegation tail — sizing and stop discipline matter more than the fundamental view.
Phase C — Judge people & books
Lens 9 · Management
CEO & Chairman: Dr. Yuping Huang — founder/principal of QPhoton (the photonics company QCi reverse-merged in June 2022), and the architect of the Core Photonics / EQC technology. He signs the 10-K as Chairman of the Board and CEO (Principal Executive Officer); a new employment agreement was executed Dec 16, 2025. Vice Chairman: Robert Fagenson (a Wall Street / former NYSE-governance figure).
- Track record: Huang is a credentialed photonics scientist (the technology is genuinely his). What he has not demonstrated is commercialization — six-plus years post-merger, revenue is sub-$1M. The "build" here is scientific and capital-markets, not commercial.
- Tenure & skin in the game: founder-CEO; the 10-K references Huang holding ~10.9% of common stock — though that reference predates the 86.3M-share 2025 raise, so his current economic stake is materially diluted.
insider-transactions.csv not present — insider buy/sell pattern not verifiable from the research layer (chase via Form 4s).
- Capital allocation — this is the whole story. Management's defining act was raising $1.475B in equity in 2025 at elevated prices — opportunistic, value-accretive to the company's balance sheet (and arguably the single best decision available: monetize the theme bubble to fund the science). They then deployed $110M of it into the LSI bankruptcy purchase — a cheap, strategically-coherent vertical-integration buy. But: ROE/ROIC are deeply negative; the cash is parked in Treasuries/money-market earning interest, not yet generating operating returns. The capital-allocation grade is "raised brilliantly, deployment unproven."
- Red flags: (a) material weaknesses in internal controls persisting through FY2025 (Lens 10); (b) a securities class action + four derivative suits naming current/past officers and directors; (c) short-sellers allege related-party revenue and misrepresentation (Lens 13); (d) G&A up 111% partly on "ongoing litigation" and "multiple financings, M&A" legal — a lot of motion, little operating output.
- Archetype: founder-scientist + capital-markets operator, not a commercial operator. For this stage that is a double-edged implication: good at raising money and advancing science, structurally weak at converting either into revenue or institutional-grade controls.
Lens 10 · Forensic Red Flags
Regulatory findings (required sub-section):
- SEC Litigation Releases / AAERs: None. Per the pre-fetched file, "total_sec_findings: 0" — no LR or AAER names QCi in 2021-06-17 → 2026-06-17 via EDGAR EFTS.
- Non-SEC enforcement (web check): No FTC/DOJ/SEC government enforcement action, subpoena, settlement or penalty found in 2025–2026; the legal activity is private securities class action, not government enforcement.
- 10-K Item 3 (Legal Proceedings) — company's own disclosure:
- Securities Class Action (NJ District Court, filed Feb 25, 2025): class period Mar 30, 2020 – Jan 15, 2025, §10(b)/20(a), alleging false/misleading statements and omissions about "the Company's customers, contracts and business operations." Second amended complaint filed Feb 13, 2026; QCi intends to move to dismiss. Unresolved.
- Four shareholder derivative actions (Mar/May/Jun/Sep 2025) against current/past officers & directors — breach of fiduciary duty, waste, unjust enrichment, common-law fraud, Exchange-Act violations. All stayed pending the class-action MTD.
- BV Advisory matter (QPhoton legacy) — settled Jul 17, 2025: QCi paid $750,000 + issued 1,900,000 shares to Barksdale/BV Advisory; resale S-1 effective Aug 4, 2025.
- Verdict line: Material litigation exists and is unresolved — a securities-fraud class action (period ending Jan 15, 2025) plus four stayed derivative suits — verified via SEC EDGAR EFTS (0 LR/AAER), web search (no govt enforcement), and 10-K Item 3, as of 2026-06-18.
Accounting risk map:
- Internal controls — MATERIAL WEAKNESS, the headline forensic flag. Disclosure controls and ICFR were "not effective" as of 12/31/2025. Root cause: insufficient trained accounting staff, inadequate control environment, insufficient segregation of duties, inadequate risk-assessment process. These weaknesses persisted across FY2023, FY2024 and FY2025 — i.e. unremediated for three straight years. For a company whose short-thesis is "fabricated revenue," ineffective controls is the most damaging possible disclosure.
- Revenue recognition: revenue is tiny but the quality is the issue — short-sellers allege a portion was related-party (Lens 13). With ineffective controls, revenue-recognition risk is elevated despite the trivial dollar amount. Post-LSI, purchase accounting and the consolidation of an acquired (bankrupt) entity's revenue introduce fresh estimation risk.
- Cash vs. earnings divergence: net loss $(18.7M) but operating cash used $(30.3M) — earnings understate the cash burn because of non-cash interest income accrual timing and the warrant gain. The "improving net loss" narrative diverges from worsening cash burn. This is the right direction of skepticism: trust the $51M operating loss, not the $18.7M net loss.
- Derivative/warrant liability (critical audit matter): the QPhoton warrant liability ($7.8M at 12/31/25) is marked to market each period using significant management judgment; the auditor flagged its valuation as a critical audit matter. Non-cash, but it injects earnings volatility and a judgment-dependent estimate.
- SBC: stock-based comp is a recurring non-cash add-back; option pool churn was heavy (7.2M options exercised in 2025) — dilutive and flattering to non-GAAP if presented.
- Dilution: shares went 129.0M → 224.2M (12/31/25) → 225.5M (May 2026) — ~75% share-count growth in one year. The balance sheet was built entirely by issuing stock into a theme bubble.
Phase D — Project & stress-test
Lens 11 · Forward Projection
This is an operating battery, but QUBT is operationally pre-commercial, so an EPS projection is near-meaningless — the right framework is cash runway × the option value of the technology, with EPS shown only to make the loss trajectory explicit. No forecast.ts create is logged (breadth/watchlist loop).
Runway (the number that matters): ~$1.46B liquidity at Q1-26 ($257.7M cash + ~$1.2B investments) against an operating burn trending to ~$80–100M/yr post-LSI. Runway is effectively a decade+ absent a major fab build — the company cannot run out of money on any reasonable horizon. The risk is value erosion and dilution, not insolvency.
EPS path (next three fiscal years, FY2026–FY2028) — all ``, base case:
- Inputs: organic quantum revenue stays sub-$5M; LSI contributes ~$15–25M/yr; opex $90–120M/yr (R&D + G&A + FAB-2 ramp); non-operating interest income ~$40–50M/yr on the $1.5B at ~3%; share count creeping up modestly (less raise pressure given the war chest).
- FY2026E EPS ~$(0.30) to $(0.45). FY2027E ~$(0.35). FY2028E ~$(0.40) as FAB-2 spend hits. Bull path narrows losses only if LSI scales fast or a real foundry order book appears; bear path is wider losses + a capital-intensive fab that consumes the cash hoard. There is no credible path to positive EPS inside three years on disclosed economics.
Conclusion: you are not buying earnings; you are buying (a) $1.5B of cash ($6.6/share of net cash+investments ) and (b) a call option on photonics/TFLN/quantum commercialization. At ~$11/share and ~$2.5B cap, ~$1B of the market cap is the technology option above net liquidity — that is the bet.
Lens 12 · Bull vs Bear
Bull case. QCi monetized the quantum theme bubble flawlessly — $1.475B raised — and now sits on a fortress balance sheet with a decade of runway while competitors burn. Room-temperature photonics is a genuinely differentiated architecture; the TFLN foundry addresses a real, fast-growing PIC/TFLN market (cited 20–39% CAGRs ); and the LSI bankruptcy purchase bought a real III-V fab, packaging, and aerospace/defense revenue for a distressed $110M. If any of photonic optimization, reservoir-computing AI accelerators, photonic sensing, or merchant TFLN foundry hits product-market fit, the option pays off many times over — and the company has the cash to wait for it. Catalysts: government quantum funding, defense contracts via LSI, a marquee foundry customer, continued sector melt-ups.
Bear case. Three impairment risks: (1) the fraud allegation is true enough to stick — the class action over customers/contracts/NASA/foundry claims resolves badly, or the unremediated material weaknesses surface a restatement; (2) the technology never commercializes — six years and <$1M revenue is not a base rate that improves easily; the science is real but the market isn't paying; (3) the cash hoard gets consumed by a capital-intensive FAB-2 with no demand, converting a balance-sheet story into a cash-incineration story. Expectations baked into price: ~$1B above net cash for a business with $682K of revenue and ineffective controls — the market is pricing a successful pivot that has not started.
Pre-mortem (18 months out, thesis broke): the class action survived the motion to dismiss (or QCi settled expensively), confirming the market's worst read of the customer/foundry claims; FAB-2 capex started without an order book; the quantum theme deflated (as it began to on June 16, 2026 ); the stock re-rated toward net cash (~$6–7) and the ~$1B option premium evaporated. The cash protected against zero, but holders still lost ~40%+ from ~$11.
Are multiples too high? On any operating metric, absurdly (P/S ~3,670× organic). But the relevant valuation is sum-of-parts: net cash ~$6.6/share + an option. The option is overpriced relative to demonstrated commercial traction; the cash is not. So: too high, but with a hard floor.
Contrarian view (what the market refuses to see): Both sides are wrong about what this is. Bulls think it's a quantum-computing company (it has no quantum-computing revenue); bears think it's a fraud headed to zero (it has $1.5B of real, audited cash and now owns a real fab). It is neither — it is a closed-end fund trading at a premium to NAV, where the premium is a venture-style call option on its own R&D, run by a scientist who is excellent at raising money and unproven at selling product. Priced that way, the asymmetry is "limited downside to net cash, lottery upside on commercialization" — but you are paying a ~$1B premium for the lottery ticket.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case. Two professional short-sellers already wrote this thesis and the market believed them enough to spawn a class action:
- Iceberg Research (Nov 2024): called QUBT a "perma-scam" and alleged the foundry "will amount to nothing".
- Capybara Research (Jan 2025): called it a "rampant fraud," alleging (a) QCi grossly misrepresented its NASA relationship — "NASA confirmed... they have no relationship with QUBT beyond a single $26,000 'computer programming' contract"; (b) fabricated revenues through related-party transactions; (c) misrepresented the AZ facility as a "fully operational foundry" when it is "merely a small R&D lab".
Where the business structurally breaks:
- Revenue concentration is near-total and possibly related-party. $682K from a handful of exploratory contracts; if the short-sellers are right that some was related-party, the organic revenue is even smaller than it looks. The class-action class period (ends Jan 15, 2025) lines up exactly with the Capybara report.
- The moat (TFLN foundry) is the exact claim under attack. If AZ Chips is an R&D lab dressed as a foundry, the differentiator is marketing, not manufacturing — and FAB-2 becomes a capital sink, not a growth engine.
- Ineffective controls for three years is the short-seller's gift: it makes "fabricated revenue" credible and a restatement plausible.
- Most dangerous competitor bulls underrate: not IonQ — it's classical computing + the rest of the well-funded quantum field (IBM, Google, IonQ, PsiQuantum, D-Wave) that will define "real" quantum/photonics commercialization and leave a sub-scale player stranded.
- Worst capital-allocation read: issuing 86.3M shares to build a $1.5B treasury can be framed as dilution-into-hype that enriches the enterprise's optionality while existing holders' per-share claim on the technology shrinks — and parking it in T-bills is an admission there is no high-return operating use for it yet.
- Assumptions that must hold for ~$11: that the class action is meritless, that controls get fixed without a restatement, that the foundry is real and scales, and that the quantum theme keeps the premium alive. If growth disappoints 20–30% (i.e. LSI underdelivers and organic stays flat), there's no earnings cushion — the stock re-rates straight to net cash.
- Single scenario that permanently impairs: an adverse class-action outcome or SEC enforcement validating the misrepresentation claims — reputational + the foundry narrative dies together. Plausibility: non-trivial (the case survived to a second amended complaint), though no government enforcement exists yet.
Lens 14 · Management Questions (ordered by information value)
- Of FY2025's $682K revenue, what portion was from related parties or entities affiliated with officers, directors, or their networks — and will you disclose customer-by-customer?
- The securities class action alleges misrepresentation of your NASA relationship; precisely what is the current scope and dollar value of all active NASA/US-government agreements?
- The AZ Chips Facility — is it producing TFLN chips for paying external foundry customers today? Name the foundry customers and the revenue, or confirm it is pre-revenue R&D.
- Internal controls have been "not effective" for three consecutive fiscal years (2023–2025); what is the dated remediation plan, and have you concluded there is no risk of restatement of any period in the class-action window?
- What is FAB-2's expected capex, the demand/order book underwriting it, and the go/no-go gate — and what happens to the cash hoard if foundry demand doesn't materialize?
- What did LSI generate in revenue, gross margin, and operating loss in the 12 months before you bought it out of bankruptcy, and what is your standalone organic (ex-LSI) revenue plan for FY2026–27?
- Why was LSI available via a Section 363 bankruptcy sale — what failed at Luminar Semiconductor, and what convinces you those problems don't transfer?
- With ~$1.5B in Treasuries/money-market earning interest, what is the hurdle-rate framework for deploying it into operations vs. continuing to clip the coupon?
- You raised $1.475B in 2025 at elevated prices; do you intend to raise further, and how do you weigh further dilution against the existing war chest?
- What is the single named, multi-year, recurring commercial contract that best proves product-market fit for any QCi product — and if none exists, when will one?
- Dr. Huang — what is your current personal economic ownership after the 2025 raises, and have you bought shares in the open market?
- Which of your four product lines (Dirac/EQC, reservoir-computing AI, photonic sensing, TFLN foundry) gets the marginal R&D dollar, and why — or are you spreading too thin?
- How do you respond, point by point, to Capybara's specific claim that the facility is "merely a small R&D lab" and revenue was "fabricated through related-party transactions"?
- What is your realistic timeline to positive gross margin at scale and to operating cash-flow breakeven, and what revenue level does that require?
- If the quantum-computing theme deflates and the stock trades to net cash, does your strategy change — and would you consider returning capital?